Compare Stocks → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:GEMPOTCMKTS:NWBONASDAQ:SAVANASDAQ:VCNXNASDAQ:ZYNE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGEMPGemphire Therapeutics$4.34+0.9%$4.97$0.24▼$1.49$64.54M2.82127,174 shs21,612 shsNWBONorthwest Biotherapeutics$0.52-13.4%$0.56$0.40▼$1.09$716.10M-0.671.69 million shs4.25 million shsSAVACassava Sciences$20.29-0.6%$22.67$12.32▼$32.10$883.08M-0.42706,552 shs469,129 shsVCNXVaccinex$7.41-0.5%$8.64$7.16▼$100.80$6.65M0.7610,810 shs17,648 shsZYNEZynerba Pharmaceuticals$1.30+2.4%$1.30$0.25▼$1.40$70.12M1.32515,333 shs862,700 shs5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGEMPGemphire Therapeutics+0.93%-1.14%-22.36%+17.41%+494.28%NWBONorthwest Biotherapeutics-13.50%+6.97%-4.86%-25.96%-12.97%SAVACassava Sciences-0.64%-4.20%-11.78%-9.86%+19.40%VCNXVaccinex-1.20%-10.72%-12.93%-20.38%-91.45%ZYNEZynerba Pharmaceuticals0.00%0.00%0.00%0.00%+195.45%Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANWBONorthwest BiotherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASAVACassava Sciences3.4564 of 5 stars3.50.00.04.72.90.00.6VCNXVaccinexN/AN/AN/AN/AN/AN/AN/AN/AZYNEZynerba PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGEMPGemphire TherapeuticsN/AN/AN/AN/ANWBONorthwest BiotherapeuticsN/AN/AN/AN/ASAVACassava Sciences3.00Buy$124.00511.14% UpsideVCNXVaccinexN/AN/AN/AN/AZYNEZynerba Pharmaceuticals2.25Hold$1.11-14.62% DownsideCurrent Analyst RatingsLatest GEMP, NWBO, SAVA, ZYNE, and VCNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/5/2024SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$124.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGEMPGemphire TherapeuticsN/AN/AN/AN/A$0.54 per shareN/ANWBONorthwest Biotherapeutics$1.93M320.94N/AN/A($0.06) per share-8.65SAVACassava SciencesN/AN/AN/AN/A$3.26 per shareN/AVCNXVaccinex$280K23.55N/AN/A$21.86 per share0.34ZYNEZynerba PharmaceuticalsN/AN/AN/AN/A$1.01 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGEMPGemphire Therapeutics-$23.64MN/A0.00∞N/AN/A-419.70%-173.05%N/ANWBONorthwest Biotherapeutics-$62.60M-$0.06N/A∞N/A-3,240.11%N/A-207.51%5/8/2024 (Estimated)SAVACassava Sciences-$97.22M-$2.32N/A12.15N/AN/A-57.53%-52.58%5/6/2024 (Estimated)VCNXVaccinex-$19.82M-$84.56N/A∞N/AN/A-2,667.31%-475.55%4/1/2024 (Estimated)ZYNEZynerba Pharmaceuticals-$35.04M-$0.80N/AN/AN/AN/A-90.03%-72.62%N/ALatest GEMP, NWBO, SAVA, ZYNE, and VCNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/5/2024Q4 2023NWBONorthwest BiotherapeuticsN/A-$0.02-$0.02-$0.02N/A$0.45 million2/28/2024Q4 2023SAVACassava Sciences-$0.40-$0.50-$0.10-$0.50N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGEMPGemphire TherapeuticsN/AN/AN/AN/AN/ANWBONorthwest BiotherapeuticsN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/AVCNXVaccinexN/AN/AN/AN/AN/AZYNEZynerba PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGEMPGemphire TherapeuticsN/A0.670.67NWBONorthwest BiotherapeuticsN/A0.090.09SAVACassava SciencesN/A9.139.13VCNXVaccinexN/A0.350.35ZYNEZynerba PharmaceuticalsN/A3.433.43OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGEMPGemphire Therapeutics17.53%NWBONorthwest Biotherapeutics0.04%SAVACassava Sciences38.05%VCNXVaccinex50.11%ZYNEZynerba Pharmaceuticals11.23%Insider OwnershipCompanyInsider OwnershipGEMPGemphire Therapeutics22.70%NWBONorthwest Biotherapeutics9.40%SAVACassava Sciences9.00%VCNXVaccinex51.30%ZYNEZynerba Pharmaceuticals13.04%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableGEMPGemphire Therapeutics914.87 millionN/ANot OptionableNWBONorthwest Biotherapeutics251.19 billion1.08 billionNot OptionableSAVACassava Sciences2943.25 million39.34 millionOptionableVCNXVaccinex38890,000434,000OptionableZYNEZynerba Pharmaceuticals2553.94 million46.91 millionOptionableGEMP, NWBO, SAVA, ZYNE, and VCNX HeadlinesSourceHeadlineHarmony Biosciences Reports Strong Third Quarter 2023 Financial Resultsfinance.yahoo.com - October 31 at 7:57 AMWhy Shares of Harmony Bioscience Are Falling on Fridayfool.com - October 13 at 12:59 PMNew Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapiesmarkets.businessinsider.com - October 11 at 9:47 AMHARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINEfinance.yahoo.com - October 11 at 9:47 AMH.C. Wainwright analysts reiterates a Buy rating for Zynerba Pharmaceuticals Inc (ZYNE)knoxdaily.com - October 10 at 1:59 PMAnalysts: ZYNE stock price target of $1.25 in 12 monthsknoxdaily.com - October 5 at 6:47 PMImportant Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructionsfinance.yahoo.com - October 4 at 7:33 PMExamining the Potential Price Growth of Zynerba Pharmaceuticals Inc (ZYNE)knoxdaily.com - October 2 at 3:14 PM20 Countries With Highest Rate of Epilepsyfinance.yahoo.com - September 29 at 6:24 PMZynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023finance.yahoo.com - September 29 at 1:23 PMHarmony Biosciences extends deadline for Zynerba shareholders on up to $200M dealbizjournals.com - September 27 at 2:42 PMZynerba Pharmaceuticals Inc [ZYNE] Investment Appeal on the Riseknoxdaily.com - September 25 at 8:15 PMZynerba Pharmaceuticals Inc. (ZYNE) rating reiterates by H.C. Wainwrightknoxdaily.com - September 20 at 12:12 PMNegative sentiment towards ZYNE reflected in surge in short interestknoxdaily.com - September 15 at 8:27 PMInsider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals Incfinance.yahoo.com - September 14 at 11:23 PMZynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposiumfinance.yahoo.com - September 14 at 6:23 PMZynerba Pharmaceuticals Hit With Shareholder Suit in Pa. Over Allegedly Inadequate Proxy Statementlaw.com - September 11 at 4:04 PMPositive sentiment towards ZYNE reflected in decline in short interestknoxdaily.com - September 8 at 5:19 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, ZYNE, KLRbakersfield.com - August 31 at 5:00 PMHC Wainwright & Co. Downgrades Zynerba Pharmaceuticals (ZYNE)msn.com - August 16 at 4:20 AMHarmony Makes Rare Disease Play with Potential $200M Zynerba Buyoutbiospace.com - August 15 at 6:19 PMZynerba Pharma (NASDAQ: ZYNE) up 300% - The contingents are worth how much?dhakatribune.com - August 15 at 6:19 PMIs Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - August 15 at 6:19 PMZynerba Pharmaceuticals Shares Soar on Harmony Biosciences Deal >ZYNEmarketwatch.com - August 14 at 9:48 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsGemphire TherapeuticsNASDAQ:GEMPGemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.Northwest BiotherapeuticsOTCMKTS:NWBONorthwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.Cassava SciencesNASDAQ:SAVACassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.VaccinexNASDAQ:VCNXVaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.Zynerba PharmaceuticalsNASDAQ:ZYNEZynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.